Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

Previous studies showed that the combination of rituximab, gemcitabine and oxaliplatin (R-GemOx) achieved high efficacy with a low toxicity profile in relapsed and refractory DLBCL. This regimen might be considered a putative treatment option for elderly patients. To our knowledge, the efficacy and safety of R-GemOx when given as first-line therapy in elderly patients with DLBCL remains unknown. The investigators therefore developed a two-weekly regimen of rituximab combined with GemOx regimen as first line treatment in elderly DLBCL and investigate its efficacy and safety. Primary Outcome Measures: * overall response rate Secondary Outcome Measures: * progression free survival * overall survival * safety and toxicity Enrollment: 60 Study Start Date: August 2012 Primary Completion Date: Dec 2015